Kymera Results Presentation Deck
●
●
●
Meeting Summary
Kymera platform and discovery engine have been validated across several programs in
patients with cancer and inflammatory diseases, with fidelity of translation of PK, PD and
safety
Kymera's unique target selection strategy, using TPD to drug undrugged targets, has been
validated, with initial demonstration of IRAK4 degradation providing a biologically and
clinically differentiated/superior profile than SMI
KT-474 data positions this mechanism and drug as a potential best in class oral drug in HS,
AD and a broader variety of immune-inflammatory diseases with large market opportunity
potential
The successful target selection strategy, molecular design, discovery and clinical execution
and insights will allow acceleration and expansion of our pipeline in areas of high unmet
need and large commercial opportunities
●
In 2023 Kymera expects to share an expanded strategy to accelerate the path towards a
disease agnostic global biotech
KYMERA Ⓒ2022 KYMERA THERAPEUTICS, INC.
PAGE 62View entire presentation